

Emergent Technologies, Inc. Hires Vice President of Business Development

AUSTIN, TX, January 25, 2008 – Emergent Technologies, Inc. (ETI), an Austin-based life sciences venture firm, has hired Gregory Pogue, Ph.D., as the firm's Vice President of Business Development. Dr. Pogue will serve a dual role as an integral member of ETI's senior management team as well as Executive Vice President and Managing Director of ETI's three immunology-related companies, Receptor Logic, Pure Protein and Pure Vaccines. His responsibilities include evaluating the commercial potential of new technologies and building industry partnerships to effectively commercialize products.

"We are very pleased that Gregory has joined ETI and welcome him to our executive team," said Thomas A. Harlan, President and CEO. "His business and product development experience make him eminently well-suited for this position. Gregory will play a key role in our future growth."

Dr. Pogue brings to ETI more than twenty years of experience in biologic development, spanning research management, biologic regulation, and intellectual property development and licensing. He most recently served as Licensing Associate for the University of Texas at Austin where he negotiated licenses with companies ranging from newly formed startups to Fortune 500 enterprises.

Before coming to Texas, Dr. Pogue served as Vice President of Research and Development at Large Scale Biology Corporation (LSBC), where he managed a broad development program involving product development and preclinical and clinical testing of numerous lead compounds, including two receiving Orphan Drug Designation from the FDA and 16 successfully completing early clinical trials. He also developed licensing and R&D contracts with corporate, academic, and government entities and supervised collaborative research relationships. Prior to joining LSBC, Dr. Pogue worked in the U.S. FDA's Center for Biologics Research and Evaluation as a scientist with Investigational New Drug and Biological Licensing Application review responsibilities.

Gregory Pogue stated, "I am excited to join ETI's team of technology commercialization experts. The firm has created a substantial platform for growth through more than eighteen years of invention capital development. I anticipate contributing to even greater progress and success for ETI's investors, the firm's portfolio companies and the economy of the region."

--more--

About Emergent Technologies, Inc.

Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on the technology assets unique to their region. ETI is pioneering a unique business approach the firm describes as *invention capital*. In addition to the traditional venture capital approach of raising and investing funds, ETI drives the selection and expansion of each investment's intellectual property, the key asset to most technology-based start-up companies. For more information, visit the company website www.etibio.com

###

Media Contact:

Sandra Oak
Nsight Public Relations
Tel: 321-591-1508
soak@nsightpr.com